Welcome to our dedicated page for Cytek Biosciences news (Ticker: CTKB), a resource for investors and traders seeking the latest updates and insights on Cytek Biosciences stock.
Cytek Biosciences, Inc. (CTKB) delivers advanced cell analysis solutions through its patented Full Spectrum Profiling technology, serving research institutions and biotech organizations worldwide. This page provides investors and industry professionals with direct access to official company announcements and relevant news updates.
Discover the latest developments including product innovations, financial results, strategic partnerships, and regulatory milestones. Our curated collection ensures you stay informed about CTKB’s progress in advancing high-resolution cellular analysis tools for scientific research.
Key updates cover earnings reports, technology enhancements, executive leadership changes, and market expansion initiatives. All content is sourced from verified channels to maintain accuracy and compliance with financial disclosure standards.
Bookmark this page for streamlined access to Cytek Biosciences’ evolving story in life sciences innovation. Check back regularly for real-time updates that matter to stakeholders in the biotech investment community.
Cytek Biosciences (NASDAQ: CTKB), a cell analysis solutions company, announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference in Miami Beach, FL. The company's management will engage in a fireside chat on June 11th at 11:40 a.m. PT / 2:40 p.m. ET. Investors and interested parties can access both live and archived webcasts of the presentation through the company's investor relations website at investors.cytekbio.com.
Cytek Biosciences (Nasdaq: CTKB) is showcasing its patented Full Spectrum Profiling™ (FSP®) technology at two major industry events: CYTO 2025 and IMMUNOLOGY2025. The company will conduct demonstrations, educational workshops, and tutorials at both conferences.
At IMMUNOLOGY2025 (May 3-7 in Honolulu), Dr. Eleanor Kincaid will host a workshop on mouse immune response characterization. The company will display its complete cell analysis solutions, including instruments, reagents, Cytek® Cloud, software, and services at Booth 801.
As a Platinum sponsor at CYTO 2025 (May 31-June 4 in Denver), Cytek will showcase its technology at Booth 401. CEO Wenbin Jiang emphasizes the company's commitment to making spectral flow cytometry more accessible, focusing on high-growth areas like immunology, oncology, and cell therapy.
The company's FSP technology aims to streamline workflows, accelerate discoveries, and enhance efficiency in both research and clinical studies.
Cytek Biosciences (Nasdaq: CTKB) has announced its upcoming first quarter 2025 financial results release, scheduled for May 8, 2025, after market close. The company will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day to discuss quarterly results, business developments, and future outlook. Interested parties can access the live audio webcast through the 'Investors' section on the company's website at investors.cytekbio.com.
Cytek Biosciences (CTKB) has launched the Cytek® Muse® Micro, a next-generation cell analyzer that enhances their iconic Guava® Muse® system. This affordable flow cytometry instrument features a user-friendly design and advanced capabilities for cell analysis applications.
The Muse Micro system includes a 488 nm blue laser with five parameters and three fluorescent channels. Key features include a compact 8x10-inch design, advanced microcapillary technology, pre-optimized kits, and Cytek InCyte™ software for simplified data analysis.
The system targets diverse markets including cell and gene therapy, drug discovery, water quality testing, biopharma, bioprocessing and beverage production. Building on the success of the original 2013 Muse system, this new analyzer aims to make sophisticated cell analysis more accessible while sustaining growth of Cytek's reagent business through additional channels.
Cytek Biosciences (CTKB) reported its Q4 and full-year 2024 financial results, showing mixed performance. Total revenue reached $200.5 million for FY2024, a 3.9% increase from 2023. The company expanded its installed base to 3,034 instruments, with 667 placements in 2024.
The company reported a net loss of $6.0 million in 2024, improved from a $12.1 million loss in 2023. Adjusted EBITDA grew significantly to $22.4 million, up 77% year-over-year. Notable developments include opening a new manufacturing facility in Singapore and completing a share repurchase of 3,971,624 shares for $21.6 million.
Looking ahead to 2025, Cytek projects revenue between $204-212 million, representing 2-6% growth. The company also announced an additional $50 million stock repurchase program for 2025.
Cytek Biosciences (Nasdaq: CTKB) has announced it will release its fourth quarter and full year 2024 financial results after market close on Thursday, February 27, 2025. The company will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day to discuss the results, business developments, and outlook. Interested parties can access the live audio webcast through the 'Investors' section of Cytek's website at investors.cytekbio.com.
Cytek Biosciences (Nasdaq: CTKB), a leading cell analysis solutions company, has announced its participation in several upcoming investor conferences in early 2025. The schedule includes:
- BTIG 12th Annual MedTech Conference in Snowbird, UT (February 11-12, 2025)
- Raymond James 46th Annual Institutional Investors Conference in Orlando, FL (March 3, 2025, at 3:25 PM ET)
- TD Cowen 45th Annual Health Care Conference in Boston, MA (March 5, 2025, at 10:30 AM ET)
- Leerink Partners Global Healthcare Conference in Miami, FL (March 10-12, 2025)
Live and archived webcasts for the Raymond James and TD Cowen conferences will be available on the company's investor relations website at investors.cytekbio.com.
Cytek Biosciences (CTKB) has announced preliminary unaudited revenue results for 2024, expecting full-year revenue between $200-201 million, representing 4% growth over 2023's $193.0 million. The company faced a $1.0 million negative foreign exchange impact.
Fourth quarter revenue is expected to be $57-58 million, showing 11-13% growth compared to Q3 2024, but a 2% decline to flat performance versus Q4 2023. The quarter was impacted by a $1.5 million negative effect from US dollar appreciation and order delays in some markets, although Asia Pacific and Rest of World markets showed strong growth.
The company will report detailed financial results and provide 2025 guidance during its earnings call expected in late February 2025.
FAQ
What is the current stock price of Cytek Biosciences (CTKB)?
What is the market cap of Cytek Biosciences (CTKB)?
